Cargando…

Vitamin D in the Prevention of Aromatase Inhibitor–Induced Musculoskeletal Symptoms: Is It Ready for Practice?

Detalles Bibliográficos
Autor principal:	Brant, Jeannine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093343/ https://www.ncbi.nlm.nih.gov/pubmed/25031952

Ejemplares similares

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)

Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)

Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms
por: Henry, N Lynn, et al.
Publicado: (2021)

The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis
por: Lu, Geling, et al.
Publicado: (2019)

The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities
por: Grigorian, Nelly, et al.
Publicado: (2022)

Use of aromatase inhibitors in practice of gynecology
por: Usluogullari, Betul, et al.
Publicado: (2015)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021)

What are the effects of systemic therapies for the prevention and treatment of aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer? - A Cochrane Review summary with commentary
por: Sen, Ekin Ilke
Publicado: (2022)

Effectiveness of intervention for aromatase inhibitor-associated musculoskeletal symptoms: A protocol for systematic review and meta-analysis
por: Meng, Hui, et al.
Publicado: (2022)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
por: Gaillard, Stéphanie, et al.
Publicado: (2011)

Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
por: Young, Nicholas A., et al.
Publicado: (2022)

Vitamin D: Are We Ready to Supplement for Breast Cancer Prevention and Treatment?
por: Crew, Katherine D.
Publicado: (2013)

Non-Musculoskeletal Benefits of Vitamin D beyond the Musculoskeletal System
por: Zhang, Sicheng, et al.
Publicado: (2021)

Art of prevention: The importance of dermatologic care when using aromatase inhibitors
por: Behbahani, Sara, et al.
Publicado: (2021)

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
por: Henry, N L, et al.
Publicado: (2010)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation
por: Tanaka, Mizue, et al.
Publicado: (2018)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Safety of aromatase inhibitors in the adjuvant setting
por: Perez, Edith A.
Publicado: (2007)

Aromatase inhibitors in stimulated IVF cycles
por: Papanikolaou, Evangelos G, et al.
Publicado: (2011)

Aromatase inhibitors in post-menopausal endometriosis
por: Polyzos, Nikolaos P, et al.
Publicado: (2011)

Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review
por: Ferrero, Simone, et al.
Publicado: (2011)

Management of aromatase inhibitor–induced arthralgia
por: Younus, J., et al.
Publicado: (2010)

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer
por: Hertz, Daniel L., et al.
Publicado: (2021)

Crucial Role of Vitamin D in the Musculoskeletal System
por: Wintermeyer, Elke, et al.
Publicado: (2016)

Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study
por: de Sire, Alessandro, et al.
Publicado: (2021)

The Role of Aromatase Inhibitors in Male Prolactinoma
por: Akirov, Amit, et al.
Publicado: (2023)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

The emerging use of aromatase inhibitors for endometriosis treatment
por: Nothnick, Warren B
Publicado: (2011)

Aromatase inhibitors in men: effects and therapeutic options
por: de Ronde, Willem, et al.
Publicado: (2011)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Potential role of aromatase inhibitors in the treatment of endometriosis
por: Abu Hashim, Hatem
Publicado: (2014)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
por: Fabian, C J
Publicado: (2007)

Dexmethylphenidate-Induced Rhabdomyolysis by Interaction With Aromatase Inhibitor
por: Huang, Derrick, et al.
Publicado: (2022)

Management of arthralgias associated with aromatase inhibitor therapy
por: Thorne, C.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_m1rmcba5klhbfditq7gevn0lqk